Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764146
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseVoyager TherapeuticsNot Yet RecruitingPhase 1
NCT07764146Not Yet Recruiting
Phase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheim...Voyager Therapeutics
NCT07762248
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular Permanent Molars With Necrotic Pulp and Apical PeriodontitisMohamed Ashraf AbdeenNot Yet RecruitingPhase 2
NCT07762248Not Yet Recruiting
Phase 2
Impact of Minimally Invasive Endodontic Treatment on the Prognosis of Mandibular...Mohamed Ashraf Abdeen
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07763158
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent Pain in Patients With Severe Knee OsteoarthritisKing Abdullah International Medical Research CenterRecruitingNot Applicable
NCT07763158Recruiting
Not Applicable
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent...King Abdullah Internation...
NCT07763587
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineNot Yet RecruitingNot Applicable
NCT07763587Not Yet Recruiting
Not Applicable
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Ben...First Teaching Hospital o...
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07764055
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)Medprin Regenerative Medical Technologies Co., Ltd.CompletedPhase 3
NCT07764055Completed
Phase 3
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)Medprin Regenerative Medi...
NCT07762911
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)University Hospital, Basel, SwitzerlandRecruitingNot Applicable
NCT07762911Recruiting
Not Applicable
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year...University Hospital, Base...
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07763938
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell MalignanciesNanjing Legend Biotech Co.Not Yet RecruitingPhase 1
NCT07763938Not Yet Recruiting
Phase 1
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relap...Nanjing Legend Biotech Co...
NCT07763392
Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the LifespanIntraneuronRecruiting
NCT07763392Recruiting
—
Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digit...Intraneuron
NCT07762547
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Beijing Tiantan HospitalNot Yet RecruitingNot Applicable
NCT07762547Not Yet Recruiting
Not Applicable
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moy...Beijing Tiantan Hospital
NCT07762092
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai LimitedNot Yet Recruiting
NCT07762092Not Yet Recruiting
—
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai Limited
NCT07762222
Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous UlcersAin Shams UniversityRecruitingNot Applicable
NCT07762222Recruiting
Not Applicable
Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chr...Ain Shams University
NCT07764185
Caring Recharge Project for Caregivers of Individuals With Alzheimer's DiseasePhotozig, Inc.Not Yet RecruitingPhase 2
NCT07764185Not Yet Recruiting
Phase 2
Caring Recharge Project for Caregivers of Individuals With Alzheimer's DiseasePhotozig, Inc.
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07763093
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival RecessionUniversity of Medicine and Pharmacy at Ho Chi Minh CityActive Not RecruitingNot Applicable
NCT07763093Active Not Recruiting
Not Applicable
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Cla...University of Medicine an...
NCT07762833
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisGalderma R&DNot Yet RecruitingPhase 3
NCT07762833Not Yet Recruiting
Phase 3
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Sub...Galderma R&D
Result Breakdown
Not yet recruiting10 (50%)
Recruiting5 (25%)
Completed2 (10%)
Active, not recruiting2 (10%)
Unknown1 (5%)
not_applicable8 (40%)
Not Specified4 (20%)
Phase 13 (15%)
Phase 22 (10%)
Phase 32 (10%)
Phase 41 (5%)